Bristol Myers Squibb Foundation launches program to tackle diversity problem in clinical trials
Over the last several months, the pandemic has amplified calls for more diverse clinical trials.
While minority populations are contracting Covid-19 at higher rates than white Americans, they are notably underrepresented in clinical trials. Black Americans make up 13% of the US population, but only 7% of participants in clinical trials, according to the FDA. And they’re being infected with Covid-19 at a 2.6 times higher rate than white Americans.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.